Clinical Trial

Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 28, 2024 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
this study aims to comprehensively evaluate the efficacy and safety profiles of rivaroxaban and warfarin during the initial postoperative period following surgical bioprosthetic valve in patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-20.
Trial Details
NCT Number NCT06476301
Lead Sponsor RenJi Hospital
Conditions Anticoagulation
Enrollment 250 participants
Start Date 2024-08-01
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-28